• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

McCarter & English Logo

  • People
  • Services
  • Insights
  • Our Firm
    • Leadership Team
    • Social Justice
    • Diversity, Equity & Inclusion
    • Pro Bono
    • Client Service Values
    • Alumni
  • Join Us
    • Lawyers
    • Summer Associates
    • Patent Professionals
    • Professional Staff
    • Job Openings
  • Locations
    • Boston
    • Philadelphia
    • East Brunswick
    • Indianapolis
    • Stamford
    • Hartford
    • Trenton
    • Miami
    • Washington, DC
    • New York
    • Wilmington
    • Newark
  • Share

Share

Browse Alphabetically:

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • All
Bankruptcy, Restructuring & Litigation
Blockchain, Smart Contracts & Digital Currencies
Business Litigation
Cannabis
Coronavirus Resource Center
Corporate
Crisis Management
Cybersecurity & Data Privacy
Delaware Corporate, LLC & Partnership Law
Design, Fashion & Luxury
E-Discovery & Records Management
Energy & Utilities
Environment & Energy
Financial Institutions
Food & Beverage
Government Affairs
Government Contracts & Global Trade
Government Investigations & White Collar Defense
Healthcare
Hospitality
Immigration
Impact Investing
Insurance Recovery, Litigation & Counseling
Intellectual Property
Labor & Employment
Life Sciences
Manufacturing
Products Liability, Mass Torts & Consumer Class Actions
Public Finance
Real Estate
Renewable Energy
Sports & Entertainment
Tax & Employee Benefits
Technology Transactions
Transportation, Logistics & Supply Chain Management
Trusts, Estates & Private Clients
Venture Capital & Emerging Growth Companies
  • Broadcasts
  • Events
  • News
  • Publications
  • View All Insights
Search By:
Insights News Printing Press
Main image for FDA Guidelines Suggest High Bar for Generic Versions of Biologic Drugs
News|Quote

FDA Guidelines Suggest High Bar for Generic Versions of Biologic Drugs

Boston Business Journal’s Bioflash

5.15.2014

As more modern drugs are created by biologic, rather than chemical, means, a set of proposed guidelines from the U.S. Food and Drug Administration this week suggests that making cheaper generic versions of those biologic drugs will be a lot more difficult. 

Maria Zacharakis, a partner at Boston law firm McCarter & English, said in an interview that the FDA has repeatedly talked about taking a “stepwise” approach to coming up with regulations surrounding biosimilars. “They are taking their time, and looking at this very carefully,” she said. Comments on the guidelines released this week will be accepted until August, after which the agency can either issue new draft guidelines or the final rules. 

But Zacharakis said the draft guidelines indicate several ways that the drug innovators may be able to ward off competition from biosimilars. The guidelines say that in order to show a new drug is a biosimilar to an existing one, the generic drugmaker will likely have to prove it’s similar in terms of both pharmacodynamics and pharmacokinetics — the study of what the body does to a drug, and what a drug does to the body. The exact methods of measuring both those properties (for instance, biomarkers used to gauge pharmacodynamics) can be patented, thereby making it impossible to prove similarity until those patents expire. Such patents would likely be applied for years after the original patent for a drug, effectively extending it significantly, she said. 

Such a case would favor drug innovators, arguably giving them more of an incentive to develop groundbreaking new drugs by allowing them to charge more for a longer period of time. 

“Pragmatically speaking, this is what the innovator companies are trying to do in the interest of their investors,” Zacharakis said.

Click for full article: “FDA Guidelines Suggest High Bar for Generic Versions of Biologic Drugs”

sidebar

pdfemail

Related People

Media item: Maria Laccotripe Zacharakis, PhD
Maria Laccotripe Zacharakis, PhD

Partner

Subscribe to our Insights
McCarter & English, LLP
Copyright © 2023 McCarter & English, LLP. All Rights Reserved.
  • Login
  • Attorney Advertising
  • Privacy
  • Awards Methodology
  • Contact
  • Subscribe
  • Sitemap

The McCarter & English, LLP website is for informational purposes only. We do not provide legal advice on this website. We can provide legal advice only to our clients in specific inquiries that they address to us. If you are interested in becoming a client, please contact us, but do not send any information about your specific legal question. We cannot serve as your lawyers until we establish an attorney-client relationship, which can occur only after we follow procedures within our firm and after we agree to the terms of the representation.

Accept Cancel